Our Mission
Our mission is to detect cancer early, when it can be cured. We are working to change the trajectory of cancer mortality and bring stakeholders together to adopt innovative, safe and effective technologies that can transform cancer care.
The Galleri test is a first-of-its-kind multi-cancer early detection (MCED) test that can detect a signal shared by more than 50 cancer types and predict the tissue type or organ associated with the signal to help healthcare providers determine next steps.
Multi-cancer early detection (MCED) blood tests analyze DNA that has been shed by all cells, including cancer cells, into the bloodstream, looking for abnormal methylation patterns on those cell-free DNA fragments that may indicate the presence of cancer.
GRAIL’s methylation technology preferentially targets the most informative regions of the genome and uses machine-learning algorithms to detect methylation patterns associated with cancer and when found, to predict the cancer signal origin.
Who We Are
GRAIL is a healthcare company innovating to solve medicine’s most important challenges. Our team of leading scientists, engineers and clinicians are on an urgent mission to detect cancer early, when it is more treatable and potentially curable.
;
It was a busy #ASCO23, and there is more data to dig into! Two GRAIL Distinguished Scientists discuss how the latest data are changing our understanding of #cancer biology and screening.
Catch up on all the GRAIL news out of ASCO: https://bit.ly/42yM1nX
When a patient receives a “cancer signal detected” result from a multi-cancer early detection test, knowing the signal origin can help lead to diagnostic resolution.
Learn more about the new analysis from PATHFINDER at #ASCO23: https://bit.ly/42qM59k
#ASCO23: Real-world data presented today confirmed our multi-cancer early detection test reliably detected a cancer signal and predicted cancer signal origin, consistent with previous clinical studies.
Learn more: https://bit.ly/43KnWMd
At #ASCO23, GRAIL and @OxfordOncology will present results from SYMPLIFY, which show strong performance of multi-cancer early detection testing in people presenting with non-specific symptoms.
Learn about the exciting potential of this analysis: https://bit.ly/3MOOpkZ
🏳️🌈 #Pride2023 is here and we are excited to kick off the festivities with events throughout the month that will aim to both celebrate and deepen our knowledge of the LGBTQIA+ community, including its history, issues, and experiences.
Not only can multi-cancer early detection detect a #cancer signal in the body, it can also determine the cancer signal origin in order to help direct follow-up testing.
Listen to #TheCancerSignal podcast to learn more about how #MCED works: https://bit.ly/414AITV
